卡培他滨联合奥沙利铂治疗进展期胃癌的近期疗效及对生活质量的影响

Short-term efficacy of capecitabine combined with oxaliplatin in treatment of patients with progressive gastric cancer and its influence on quality of life

目的探讨卡培他滨联合奥沙利铂治疗进展期胃癌的近期疗效及对生活质量的影响。方法选取经病理检查确诊的进展期胃癌患者87例,随机分为观察组44例和对照组43例。观察组给予卡培他滨联合奥沙利铂治疗,对照组给予表阿霉素+顺铂+氟尿嘧啶(ECF)方案治疗。比较2组近期疗效,详细记录治疗期间毒副反应的发生情况,并观察治疗前后生活质量的改善情况。结果观察组有效率为61.36%,显著高于对照组的39.53%(P<0.05)。观察组骨髓抑制、胃肠道反应发生率均显著低于对照组(P<0.05),丙氨酸氨基转移酶(GPT)升高、血尿素氮(BUN)升高、色素沉着及脱发等发生率均无显著差异(P>0.05)。治疗后,2组躯体、情绪、认知、角色、社会等各维度评分及总分显著增加(P<0.01),其中观察组增加幅度显著大于对照组(P<0.01)。结论卡培他滨联合奥沙利铂治疗进展期胃癌疗效好,且明显改善患者的生活质量。

Objective To explore the short-term efficacy of capecitabine combined with oxaliplatin in the treatment of patients with progressive gastric cancer and its influence on quality of life（ QOL）. Methods A total of 87 patients diagnosed as progressive gastric cancer by pathological examinations were randomly divided into observation group（ n = 44） and control group（ n = 43）. Observation group was treated with capecitabine combined with oxaliplatin,while control group was treated with ECF protocol（ epirubicin plus cisplatin plus fluorouracil）. Short-term efficacy was compared between two groups,adverse reactions were recorded in details during treatment and the improvement of QOL was observed before and after treatment in both groups. Results The response rate was61. 36% in observation group,which was significantly higher than the 39. 53% in control group（ P〈0. 05）. Observation group was significantly lower in the occurrence rates of myelosuppression and gastrointestinal responses than control group（ P〈0. 05）,but there were no significant differences between two groups in the occurrence rates of increased alanine aminotransferase（ GPT）,increased blood urea nitrogen（ BUN）,pigmentation and alopecia（ P〈0. 05）. After treatment,each dimension score of body,emotion,cognition,role and society and the total score increased significantly in both groups than treatment before（ P〈0. 01）,which increased more significantly in observation group than those in control group（ P〈0. 01）. Conclusion Capecitabine combined with oxaliplatin has excellent efficacy in the treatment of patients with progressive gastric cancer,and it can significantly improve patients＇ QOL.